Background: Nivolumab improved overall survival (OS) in patients with platinumrefractory recurrent or metastatic head and neck squamous cell carcinoma in the phase III CheckMate 141 clinical trial. Following this result, nivolumab was approved in Japan for recurrent or metastatic head and neck cancer regardless of histological subtype. However, the clinical efficacy of nivolumab for non-squamous head and neck cancer (non-Sq. HNC) remains unclear. Methods: To evaluate the efficacy of nivolumab for non-Sq. HNC, we retrospectively reviewed 28 patients (pts) treated with nivolumab for recurrent or metastatic head and neck cancer at our institution between March 2017 and January 2018. Results: Among the 28 pts, we identified 5 pts with recurrent or metastatic non-Sq. HNC. These 5 pts all received prior platinum-based chemotherapy, with 4 pts having platinum-refractory disease and 1 intolerant to platinum. Primary site was salivary glands/hypopharynx in 4/1. Pathological diagnosis was adeno carcinoma/basaloid carcinoma/salivary duct carcinoma/carcinoma ex-pleomorphic adenoma in 2/1/1/1, respectively. Median age (range) was 63 (58-81), and male/female was 4 /1. Four pts received at least 4 cycles of nivolumab, with a median cycle of 4 (1-15). According to RECIST ver1.1, one patient achieved PR, 2 pts showed SD and 2 pts had PD, corresponding to a disease control rate of 60%. The safety profile was equivalent to those in previous reports and no severe adverse reactions were seen. Conclusions: Nivolmab appeared to be beneficial and well-tolerated in pts with non-Sq. HNC and warrants further investigation for this rare disease subtype.
Background: Circulating cancer stem-like cell (cCSC) has been revealed its property of chemoresistance; however, its predictive role in prognosis of patient with breast cancer remains unclear. Methods: Forty-eight patients with stage IV breast invasive ductal carcinoma were prospectively enrolled between April 2014 and January 2016. Circulating tumour cell (CTC) test was performed by negative selection strategy and HoechstþCD45-EpCAMþ cells were identified as CTCs. The HoechstþCD45-EpCAMþCD133þ cells were identified as circulating cancer stem-like cells (cCSC). CTC analysis was performed at the baseline, 4th week and 3rd month of first line palliative chemotherapy. Results: We found that the performance status and the baseline cCSC/CTC ratio were independent prognostic factors for progression-free survival (PFS) (P ¼ 0.005 and P < 0.0001, respectively). Baseline CTCs and baseline cCSC/CTC ratio were independent prognostic factors for overall survival (OS) (both P < 0.0001). The change in cCSCs from baseline to 4th week and 3rd month was prognostic factor for PFS (P ¼ 0.011 and P < 0.001, respectively) and the change in CTCs from baseline to 4th week and 3rd month were prognostic factor for PFS and OS (P value in PFS: P < 0.001; p value in OS: P ¼ 0.012 and P ¼ 0.020). At the 3rd month response evaluation after chemotherapy, the cCSC/CTC ratio in those patients with disease control (n ¼ 36) seems to be insidiously increasing, which suggests a potential early sign of chemoresistance. Conclusion: The baseline CTCs and the baseline cCSC/CTC ratio were prognostic in survival among patients with metastatic breast cancer. In disease controlled group, the gradual increase of cCSC/CTC ratio probably suggests the upcoming failure of chemotherapy. Background: Maintenace therapy is needed after chemotherapy to breast cancer. Herbal medicines and endcrine therapy, which represent moderate therapeutic effect and low side-effect, are good choices. Jinqi medicine (JQ formula), which is a Chinese herbal formula consisted of Lonicerae Japonicae Flos (J), mongholicus (H) et al, is a fine choice. However, the active principle and mechanism remains unclear. Methods: Compounds of herbs were extracted and separated into several active parts by ethylacetate and n-butanol, and analyzed by High Performance Liquid Chromatography (HPLC) and Mass Spectrum (MS). 4T1, MDA-MB-231, SUM149, SUM159 and MDA-MB-468 breast cancer cell lines were enrolled and 4T1 xenograft model were established. Cell functions of proliferation and migration activity were measured by MTT and colony-forming unit assays, and the mitogen activated protein kinase (MAPK) signaling pathway and NF kappaB P65/P50 protein expression in tumor microenviroment were tested. Result: N-butanol related fraction (JQ-NB) and residual related fraction (JQ-RE) were confirmed, which mainly contain flavonoids and glucoside-containing compounds, respectively. In vitro, JQ-NB and JQ-RE fraction inhibited cancer cell proliferation and migration ability of 4T1, MDA-MB-231, SUM149, SUM159 and MDA-MB-468 in a dose dependent manner. In vivo, tumor volume and weight decreased significanly in JQ-NB/RE groups, especially JQ-RE was identified as the most effective solvent fraction while used by intraperitoneal injection. Meanwhile, in tumor microenvironment, the expression of phosphorylated-ERK, NF kappaB P50/P65, VEGF, EGF and TGF beta were suppressed by JQ-NB and JQ-RE, respectively. Conclusions: This study indicated that JQ-NB and JQ-RE part inhibit cell proliferation and migration activity by influenced the MAPK, NF kappaB signaling pathway and cytokines expression and it is effectiveness. In summary, JQ preparation can be used as maintenace therapy for breast cancer. 
